Integrated Treatment for Veterans with Co-Occurring Chronic Pain and Opioid Use Disorder

Information

  • Research Project
  • 10259870
  • ApplicationId
    10259870
  • Core Project Number
    UH3DA051241
  • Full Project Number
    5UH3DA051241-03
  • Serial Number
    051241
  • FOA Number
    RFA-NS-19-021
  • Sub Project Id
  • Project Start Date
    9/30/2019 - 5 years ago
  • Project End Date
    8/31/2024 - 6 months ago
  • Program Officer Name
    AKLIN, WILL
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    9/1/2021 - 3 years ago
Organizations

Integrated Treatment for Veterans with Co-Occurring Chronic Pain and Opioid Use Disorder

PROJECT SUMMARY Chronic pain is common, costly, and debilitating. Opioid prescription in the treatment of chronic pain is frequent and carries a consequent risk of poor treatment outcome, as well as higher morbidity and mortality in a clinically significant number of patients, particularly those who meet criteria for opioid dependence. Despite the alarming increases in prescription opiate misuse and opioid use disorder (OUD) nationally in the United States, there are few treatment options available that target both pain-related interference and OUD among patients with chronic pain. In military veterans, this issue is of particular importance as numerous reports indicate frequent use of opioids in the treatment of chronic pain, as well as increasing opioid-related problems. To date, there are no evidenced-based treatment options which aim to both reduce pain interference simultaneously addressing problematic opioid use. The overall aim of the present study will be to determine the efficacy of an integrated psychosocial treatment in veterans with chronic pain, who are taking buprenorphine for the treatment of OUD. To examine this aim, we will utilize a randomized design to assess the efficacy of two empirically supported interventions: Acceptance and Commitment Therapy for chronic pain and Mindfulness Based Relapse Prevention for substance use and misuse. Efficacy will be assessed by examining pain interference and substance use outcome after three months of active treatment, as well as at 6 and 12 month follow-ups. Secondary outcomes, including depression, pain-related fears, and opioid misuse risk, will also be assessed at these same follow-ups. The study will also examine the relation between within-treatment changes in treatment mechanisms, including pain acceptance, engagement in values based action, and opioid craving, and changes at post- treatment and follow-up. The results of this study will directly inform treatment of chronic pain patients and represents a significant advance in the growing and understudied problem of OUD among chronic pain patients. In addition to addressing the question of whether the treatment is feasible, it will further examine issues of treatment mechanisms to better inform the provision of treatment.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    UH3
  • Administering IC
    DA
  • Application Type
    5
  • Direct Cost Amount
    484362
  • Indirect Cost Amount
    95821
  • Total Cost
    580183
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NINDS:580183\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF NEW MEXICO
  • Organization Department
    PSYCHOLOGY
  • Organization DUNS
    868853094
  • Organization City
    ALBUQUERQUE
  • Organization State
    NM
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    871063807
  • Organization District
    UNITED STATES